By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment firm Goldman Sachs on Tuesday downgraded Cepheid shares to "Neutral" from "Buy," citing the stock's outperformance compared to its peer group and a less attractive risk/reward at current levels.

In a research note, Issac Ro noted strong performance by Cepheid's stock and expected continued growth at the company, but expressed concern over its high price-to-sales multiple of 7.4 times, compared to a median of 2.6 times for its peer group.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

In Nature this week: a Danish reference genome, and more.